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Results: A total of 325 IMRT treatment verifications have been 
performed (315 RA), with more than 700 portal images analyzed. 
Although we use a quite restrictive protocol (local gamma index) the 
average number of points that passed the mentioned criterion has 
been 95.1% (range: 83.5 – 99.9,std dev: 4%). The worse cases results 
have been found in IMRT static fields (like mantle type fields), in 
complex cases (non-coplanar 6 arcs treatment, very large fields even 
exceeding the detector size) and in RA plans with a large number of 
arcs in which the acquired images show a pattern of regions with large 
portions shielded.  We use Portal Dosimetry in each IMRT plan prior to 
treatment due mainly to the characteristics of the detector, but it has 
to be used in conjunction with other dosimetric systems. On one side 
are the limitations of the prediction algorithm, and on the other it is 
difficult to establish the acceptance levels for gamma analysis results 
especially for RA where the whole arc is acquired in one image. 
Conclusions: Portal Dosimetry is being used in routine in IMRTpre-
treatment patient-specific verifications. For most of the cases pass 
rates are quite high, but another two systems are used in conjunction 
in order to decide the acceptability of the plan. Specific acceptance 
levels guidances provided by vendor would be very helpful to users. 
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Purpose/Objective: Total body irradiation treatments are usually 
checked with in-vivo dosimetry measurements. In our institution we 
use a diodes-based in-vivo dosimetry system, composed of diodes, 
electrometer and software. A single failure in one of the components 
may make the system unusable. We aimed to evaluate Gafchromic 
EBT2 radiochromic film (International Specialty Products) as a backup 
system for diodes to perform in-vivo dosimetry for total body 
irradiation treatments. 
Materials and Methods: EBT2 films readings were compared to a 
Farmer 30013 chamber (PTW) and EDP-15 diodes (IBA) in a solid water 
phantom, in TBI conditions: 6 MV photon beam (Varian 2100 linac), 
40x40 cm2 field, SSD=315 cm, 1 cm PMMA beam spoiler. Films were 
located at the phantom surface, under a 1 cm bolus slab. Diodes were 
also at surface and ionization chamber was situated at phantom mid-
plane (9 cm depth). Two films were irradiated each time. EBT2 films 
were tested for post-irradiation time influence, linearity, accuracy 
and reproducibility. We also measured attenuation of bolus+film and 
assessed the influence of interruptions during irradiation. A film inside 
the phantom measured a PDD curve. Red channel calibration was used 
to read the films. The method was clinically tested in three patients: 
a 2x2 cm2 piece of film was affixed to patient's skin (at abdomen) 
below a 1 cm bolus slab. Film reading was converted to mid-plane 
dose and compared with diode readings. 
Results: We found that films response remains stable after around 24 
h. Dose linearity was excellent in the range 10-200 cGy. PDD 
measurement showed a dose value at mid-plane of 79.3% of maximum 
dose, while PDD measured with ionization chamber showed a value of 
80.4%. Film dose readings were within 3% respect to chamber dose 
values (mean -1.6%), except for one film (6%). Difference between 
film and diodes were within 4.6% (mean -3.2%), except for one film 
(7.5%). Film reproducibility was within 2% (10 films). Since one of the 
films showed a very different dose from the mean value (6%), 
reproducibility would drop to 1.4% if this film was not considered. No 
significant influence of interruption time was detected for an 
interruption time up to 6 min. Bolus slab and EBT2 film produced an 
attenuation of 2.5% at phantom mid-plane. Results from the three 
patients studied showed a deviation of 2.5%, 3.1% and 2.0% between 
EBT2 films and diodes. 
Conclusions: We developed a practical method to use EBT2 film as a 
backup system for diodes in TBI in-vivo dosimetry. Mean film dose 
readings differed from diodes less than 3.5%, in phantom and clinical 
conditions. EBT2 films are an adequate in-vivo dosimeter provided 
some precautions are taken: films should be read 24 h after 
irradiation and we recommend using at least 2 pieces of film for each 
location, and set up the bolus slab with film at a different position 
each session to diminish the attenuation effect. 
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Purpose/Objective: TomoDirectTM (TD) is a non-rotational treatment 
option implemented on the TomoTherapy Hi-Art system (Accuray, 
Inc., Sunnyvale, CA). It stands as an alternative to conventional linac 
system, allowing to deliver IMRT treatments with a static gantry 
position. With the introduction of TD new potentialities for the 
treatment of the whole breast are now available. Since some 
protocols recommended to systematically check the absorbed dose 
delivered in new treatment techniques to a patients’ sample 
implementing in-vivo dosimetry protocol, we decided to study the 
effectiveness of MOSFET (TN-502 RDM-H standard microMOSFET 
Thomson & Nielsen, Ottawa, ON Canada) as in-vivo dosimeters during 
TD treatment of breast cancer. 
Materials and Methods: The MOSFETs were calibrated against an 
ionization chamber type Exradin A1SL (Standard Imaging, Middleton, 
WI) using a modulated TD beam calculated on PMMA phantom. The 
entrance and exit dose calibration factors were determined in a solid 
water phantom positioning the MOSFET with the required 
hemispherical brass build-up cup. To verify the MOSFET effectiveness 
during in vivo dosimetry, dose measurements were performed on 
whole breast treatment plans created using TD two opposed 
tangential beams technique on an anthropomorphic Rando female 
thorax phantom (Phantom Laboratory, Salem, New York). 
Measurements were performed positioning MOSFET at the medial side 
on a point coincident with the red laser at 5 cm from radiopaque 
alignment marker and at the lateral side on the same defined 
reference point. This process was repeated several times to evaluate 
the reproducibility and accuracy of MOSFET measurements during 
treatment on a Tomotherapy Hi-Art unit. In vivo dosimetry was then 
performed on a total of 15 whole breast patients using the same 
procedure. Discrepancies between measured and calculated values for 
TD treatments have been evaluated. 
Results: The reproducibility of the MOSFET response is found to be 
better than 2.5% for the doses normally delivered to the patients. The 
difference between the MOSFET measured dose on Rando phantom 
and the planned dose at each point was less than 4%, with an average 
of -0.8 %± 1.7%. In vivo dose measurements show that the dose 
difference between MOSFET results and the TPS calculations was on 
average -0.7%, ranging from -4.7% to 4.8% with a standard deviation of 
the measurements of each patient less than 3%. 
Conclusions: In conclusion, MOSFET detectors are suitable for routine 
TD dose verification. 
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Purpose/Objective: The aim of this study is to develop a novel dose-
verification method for intensity-modulated radiotherapy (IMRT) that 
expands upon the traditional DTA (extended DTA) by adding 
displacement directions to the distance difference. 
Materials and Methods: The extended DTA was acquired by measuring 
the distance between the isodose lines obtained from theTreatment 
Planning System (reference isodose line) and the film dosimetry 
(evaluation isodose line) (EDR2 Films: EastmanKodak Company;) of the 
prostate IMRT case. The extended DTA is the difference between the 
points at which the reference and evaluation isodose line intersect 
with a straight line after every 10° with respect to the origin. 
Furthermore, the distance of the difference was determined as both 
'negative' and 'positive' if the evaluation isodose lines were both inside 
and outside the reference isodose lines, respectively. This latter 
assessment is useful because some reference isodose lines show low 
and high doses. The extended DTA was represented by 2D difference 
maps that use cylindrical projection. These maps show the angle in 
the horizontal axis, the dose in the vertical axis and the distance of 
difference (in millimeters) with the color scale. The extended DTA 
was performed by an in-house program and compared with the gamma 
analysis and the DTA using an OmniPro ImRT (IBA Dosimetry). The 
criterion value used for the gamma analysis and the DTA was 2mm3%, 
2mm. DTA was 2mm3%, 2mm. The extended DTA was calculated using 
max dose and 100%, 97%, 95%, 93%, 90% and 80% of the isodose lines. 
Results: The extended DTA in the 2D difference map showed a value 
